Literature DB >> 25977566

Circulating Markers of Liver Function and Cardiovascular Disease Risk.

Giovanni Targher1, Christopher D Byrne2.   

Abstract

Measurement of serum concentrations of various liver enzymes and other nonenzymatic proteins and metabolites of heme metabolism (eg, bilirubin) is often undertaken in clinical practice. Measurement of these liver function tests is simple, quick, and relatively inexpensive. However, interpreting the liver function test results in patients without evidence of liver disease is often challenging. Concentrations of some of liver enzymes, such as γ-glutamyltransferase or alkaline phosphatase, and concentrations of liver-derived metabolites, such as bilirubin, may be influenced by metabolic processes beyond the liver, sometimes making interpretation of the test results difficult. This scenario frequently occurs both in individuals at risk of cardiovascular disease and in patients with known cardiovascular disease, often resulting in the clinicians ignoring the test results. In this brief review, we discuss the evidence for associations between key serum liver function tests and cardiovascular disease risk and where associations are robust; we provide an interpretation for possible mechanistic links between the liver function test and cardiovascular disease.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  bilirubin; cardiovascular diseases; gamma-glutamyltransferase; transaminases

Mesh:

Substances:

Year:  2015        PMID: 25977566     DOI: 10.1161/ATVBAHA.115.305235

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  18 in total

Review 1.  Role of circulating factors in cardiac aging.

Authors:  Antonio Cannatà; Gabriella Marcon; Giovanni Cimmino; Luca Camparini; Giulio Ciucci; Gianfranco Sinagra; Francesco S Loffredo
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost.

Authors:  Wai Hoong Chang; Stefanie H Mueller; Sheng-Chia Chung; Graham R Foster; Alvina G Lai
Journal:  J Transl Med       Date:  2022-01-03       Impact factor: 5.531

3.  Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program.

Authors:  Giulia Ferrannini; Norman Rosenthal; Michael K Hansen; Ele Ferrannini
Journal:  Cardiovasc Diabetol       Date:  2022-07-04       Impact factor: 8.949

4.  Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?

Authors:  Gabriel Tayguara Silveira Guerreiro; Larisse Longo; Mariana Alves Fonseca; Valessa Emanoele Gabriel de Souza; Mário Reis Álvares-da-Silva
Journal:  Hepatol Int       Date:  2021-03-10       Impact factor: 6.047

Review 5.  Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

Authors:  Alessandro Mantovani; Stefano Ballestri; Amedeo Lonardo; Giovanni Targher
Journal:  Dig Dis Sci       Date:  2016-01-25       Impact factor: 3.199

Review 6.  Hepatic Shock Differential Diagnosis and Risk Factors: A Review Article.

Authors:  Hassan Soleimanpour; Saeid Safari; Farzad Rahmani; Arezu Nejabatian; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2015-10-10       Impact factor: 0.660

7.  The aspartate aminotransferase-to-alanine aminotransferase ratio predicts all-cause and cardiovascular mortality in patients with type 2 diabetes.

Authors:  Giacomo Zoppini; Vittorio Cacciatori; Carlo Negri; Vincenzo Stoico; Giuseppe Lippi; Giovanni Targher; Enzo Bonora
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

8.  Gamma-glutamyl transferase variability can predict the development of end-stage of renal disease: a nationwide population-based study.

Authors:  Da Young Lee; Kyungdo Han; Ji Hee Yu; Sanghyun Park; Jee-In Heo; Ji A Seo; Nam Hoon Kim; Hye Jin Yoo; Sin Gon Kim; Seon Mee Kim; Kyung Mook Choi; Sei Hyun Baik; Yong Gyu Park; Nan Hee Kim
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

9.  Association of High-Intensity Binge Drinking With Lipid and Liver Function Enzyme Levels.

Authors:  Daniel B Rosoff; Katrin Charlet; Jeesun Jung; Jisoo Lee; Christine Muench; Audrey Luo; Martha Longley; Kelsey L Mauro; Falk W Lohoff
Journal:  JAMA Netw Open       Date:  2019-06-05

10.  Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case-Control Study.

Authors:  Hui-Hui Liu; Ye-Xuan Cao; Di Sun; Jing-Lu Jin; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Ying Gao; Qiu-Ting Dong; Xi Zhao; Sha Li; Yan Zhang; Geng Liu; Jian-Jun Li
Journal:  Clin Transl Gastroenterol       Date:  2019-02       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.